Katherine Fuh, MD
Gynecologic Oncology · San Francisco, CANPI 1740462316
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,274 of the $26,240 with a category attached, or 84.9%. 13 manufacturers reported payments, led by GSK at 26.9% of the total.
Across 35 payments — averaging $749.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$7K
- Astrazeneca UK Limited$5K
- Eisai Inc.$4K
- AstraZeneca$3K
- Myriad Genetic Laboratories, Inc.$3K
- Genentech, Inc.$2K
- plus $2K from 7 others
What the payments were for
- Consulting fees$22,27485%
- Grants$1,7337%
- Travel & lodging$4272%
- Food & beverage$1,7417%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $7,056 |
| Astrazeneca UK Limited | 1 | $4,900 |
| Eisai Inc. | 5 | $3,623 |
| AstraZeneca | 5 | $3,313 |
| Myriad Genetic Laboratories, Inc. | 2 | $3,000 |
| Genentech, Inc. | 1 | $2,200 |
| Tesaro, Inc. | 4 | $1,556 |
| Karyopharm Therapeutics Inc. | 2 | $193 |
| Seagen Inc. | 1 | $120 |
| Novo Nordisk | 1 | $100 |
| Merck | 1 | $95 |
| Intuitive Surgical | 1 | $63 |
| Coopersurgical, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,240 in reported general payments places this provider in the 80th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 12 | $206 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in San Francisco
- John ChanSan Francisco$2M
- Lejla DelicSan Francisco$16K
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
- Rebecca BrooksSacramento$133K
- Kenneth KimWest Hollywood$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.